FY2025 Earnings Estimate for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities research analysts at Lifesci Capital issued their FY2025 earnings estimates for ABIVAX Société Anonyme in a research note issued on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($3.14) for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

ABVX has been the subject of several other reports. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Finally, Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $38.00.

ABIVAX Société Anonyme Stock Down 3.4 %

Shares of ABIVAX Société Anonyme stock opened at $7.09 on Wednesday. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $16.63. The company has a fifty day moving average of $6.78 and a 200-day moving average of $8.42.

Institutional Trading of ABIVAX Société Anonyme

Institutional investors have recently modified their holdings of the company. Kennedy Capital Management LLC raised its position in ABIVAX Société Anonyme by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock valued at $1,650,000 after purchasing an additional 1,656 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme in the fourth quarter worth $29,000. R Squared Ltd bought a new stake in ABIVAX Société Anonyme in the fourth quarter valued at $36,000. Finally, BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.